FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155111125> ?p ?o ?g. }

• W2155111125 endingPage "1441" @default.
• W2155111125 startingPage "1437" @default.
• W2155111125 abstract "Melanoma is one of the most aggressive skin cancers. Recently, selective MEK inhibitors have shown efficacy in patients with advanced BRAF- and NRAS-mutant melanoma. Soon after the initiation of clinical oncology trials with MEK inhibitors, it was observed that some participants developed an eye condition resembling central serous chorioretinopathy. The present article addresses the clinical features and management of these MEK inhibitor-associated retinal syndromes.Thirty-two patients with advanced cutaneous melanoma were treated with the selective MEK inhibitor binimetinib (MEK162) in three different Phase 1b or 2 clinical trials. Twenty patients on binimetinib monotherapy and 12 on binimetinib plus RAF inhibitor [pan-kinase RAF inhibitor RAF265 (n = 7) or selective BRAF inhibitor encorafenib (LGX818) (n = 5)] combination therapy underwent ophthalmological examinations at regular intervals, including determination of best corrected visual acuity, perimetry, colour vision testing, dilated fundus examination, and multimodal imaging.Grade 1-2 bilateral retinopathies with multiple lesions were observed in 13 of 20 patients on binimetinib monotherapy, 4 of 7 patients on binimetinib plus RAF265 combination therapy, and 2 of 5 patients on binimetinib plus encorafenib combination therapy. In this study population, the rate ranged from 40% to 65%. Retinopathy events appeared during the first 4 weeks, and in some cases, during the first few days of treatment. Patients reported mild and only short-lived visual symptoms. Optical coherence tomography revealed neuroretinal elevations. Central retinal thickness and volume showed dose-dependent increases after the start of treatment, followed by a marked decrease despite continued treatment, which was associated with symptom resolution. No vascular abnormalities were found with fluorescein and indocyanine green angiography.Treatment with the selective MEK inhibitor binimetinib as a single agent or in combination with RAF inhibitors induced transient retinopathy with multiple bilateral lesions in some patients. Binimetinib-induced retinopathy was usually mild, self-limiting, and tolerable as visual function was not seriously impaired." @default.
• W2155111125 created "2016-06-24" @default.
• W2155111125 creator A5006323243 @default.
• W2155111125 creator A5008000580 @default.
• W2155111125 creator A5008576931 @default.
• W2155111125 creator A5015424908 @default.
• W2155111125 creator A5016437848 @default.
• W2155111125 creator A5047381333 @default.
• W2155111125 creator A5059162808 @default.
• W2155111125 creator A5072087869 @default.
• W2155111125 creator A5089297467 @default.
• W2155111125 date "2014-07-01" @default.
• W2155111125 modified "2023-10-14" @default.
• W2155111125 title "Transient MEK inhibitor-associated retinopathy in metastatic melanoma" @default.
• W2155111125 cites W1508313938 @default.
• W2155111125 cites W1550490111 @default.
• W2155111125 cites W1969527260 @default.
• W2155111125 cites W1980262236 @default.
• W2155111125 cites W1984810353 @default.
• W2155111125 cites W1994711914 @default.
• W2155111125 cites W1996375148 @default.
• W2155111125 cites W2010646982 @default.
• W2155111125 cites W2019399290 @default.
• W2155111125 cites W2027002042 @default.
• W2155111125 cites W2042225844 @default.
• W2155111125 cites W2061952603 @default.
• W2155111125 cites W2065243720 @default.
• W2155111125 cites W2071098542 @default.
• W2155111125 cites W2080627917 @default.
• W2155111125 cites W2086571195 @default.
• W2155111125 cites W2090420216 @default.
• W2155111125 cites W2093216792 @default.
• W2155111125 cites W2097995306 @default.
• W2155111125 cites W2100738068 @default.
• W2155111125 cites W2123363005 @default.
• W2155111125 cites W2128542677 @default.
• W2155111125 cites W2130986759 @default.
• W2155111125 cites W2133253144 @default.
• W2155111125 cites W2136474966 @default.
• W2155111125 cites W2137990944 @default.
• W2155111125 cites W2144072015 @default.
• W2155111125 cites W2153216846 @default.
• W2155111125 cites W2154841567 @default.
• W2155111125 cites W2156078931 @default.
• W2155111125 cites W2156509877 @default.
• W2155111125 cites W2160834915 @default.
• W2155111125 cites W2165781249 @default.
• W2155111125 cites W2166262263 @default.
• W2155111125 cites W2382461064 @default.
• W2155111125 doi "https://doi.org/10.1093/annonc/mdu169" @default.
• W2155111125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24864047" @default.
• W2155111125 hasPublicationYear "2014" @default.
• W2155111125 type Work @default.
• W2155111125 sameAs 2155111125 @default.
• W2155111125 citedByCount "109" @default.
• W2155111125 countsByYear W21551111252014 @default.
• W2155111125 countsByYear W21551111252015 @default.
• W2155111125 countsByYear W21551111252016 @default.
• W2155111125 countsByYear W21551111252017 @default.
• W2155111125 countsByYear W21551111252018 @default.
• W2155111125 countsByYear W21551111252019 @default.
• W2155111125 countsByYear W21551111252020 @default.
• W2155111125 countsByYear W21551111252021 @default.
• W2155111125 countsByYear W21551111252022 @default.
• W2155111125 countsByYear W21551111252023 @default.
• W2155111125 crossrefType "journal-article" @default.
• W2155111125 hasAuthorship W2155111125A5006323243 @default.
• W2155111125 hasAuthorship W2155111125A5008000580 @default.
• W2155111125 hasAuthorship W2155111125A5008576931 @default.
• W2155111125 hasAuthorship W2155111125A5015424908 @default.
• W2155111125 hasAuthorship W2155111125A5016437848 @default.
• W2155111125 hasAuthorship W2155111125A5047381333 @default.
• W2155111125 hasAuthorship W2155111125A5059162808 @default.
• W2155111125 hasAuthorship W2155111125A5072087869 @default.
• W2155111125 hasAuthorship W2155111125A5089297467 @default.
• W2155111125 hasBestOaLocation W21551111251 @default.
• W2155111125 hasConcept C118487528 @default.
• W2155111125 hasConcept C126322002 @default.
• W2155111125 hasConcept C143998085 @default.
• W2155111125 hasConcept C184235292 @default.
• W2155111125 hasConcept C2776999253 @default.
• W2155111125 hasConcept C2777658100 @default.
• W2155111125 hasConcept C2778257484 @default.
• W2155111125 hasConcept C2778472372 @default.
• W2155111125 hasConcept C2781249067 @default.
• W2155111125 hasConcept C502942594 @default.
• W2155111125 hasConcept C535046627 @default.
• W2155111125 hasConcept C57074206 @default.
• W2155111125 hasConcept C71924100 @default.
• W2155111125 hasConcept C86803240 @default.
• W2155111125 hasConcept C95444343 @default.
• W2155111125 hasConceptScore W2155111125C118487528 @default.
• W2155111125 hasConceptScore W2155111125C126322002 @default.
• W2155111125 hasConceptScore W2155111125C143998085 @default.
• W2155111125 hasConceptScore W2155111125C184235292 @default.
• W2155111125 hasConceptScore W2155111125C2776999253 @default.
• W2155111125 hasConceptScore W2155111125C2777658100 @default.
• W2155111125 hasConceptScore W2155111125C2778257484 @default.

• next